
|Videos|March 28, 2019
Next Steps for LOXO-292 in RET-Mutant Medullary Thyroid Cancer
Author(s)Alexander E. Drilon, MD
Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.
Advertisement
Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers andRET-mutant medullary thyroid cancers (MTC).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Community Clinical Trials and the Lung Cancer Pipeline
2
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
3
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
4
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
5
























